Nasdaq · Technology
Cardlytics, Inc. (CDLX)
As-reported financials and recent SEC filings for Cardlytics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$212.3M
Net income
$-103.5M
Net margin
-48.7%
Diluted EPS
$-1.95
ROE
1590.2%
P/E (TTM)
—
Market cap
$27.4M
Debt / equity
-32.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $212.3M | $255.6M | $285.4M | $277.2M | $258.8M |
| Gross profit | — | — | — | — | — |
| Operating income | $-101.8M | $-195.5M | $-135.7M | $-457.8M | $-122.6M |
| Net income | $-103.5M | $-189.3M | $-134.7M | $-465.3M | $-128.6M |
| Diluted EPS | $-1.95 | $-3.91 | $-3.69 | $-13.92 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-03
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →8-K2026-05-20
View on EDGAR →Go deeper on CDLX
Search Cardlytics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.